Abstracts tagged "Disease Activity"

Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
Abstract Number: 1019 • ACR Convergence 2020
Outdoor Air Pollution and Systemic Lupus Erythematosus
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Johns Hopkins University, BALTIMORE, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Understanding the role of environmental exposures in the development of SLE and their association with SLE activity may help identify modifiable risk factors and…
Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Gerd Burmester¹, Laure Gossec², Hubert van Hoogstraten³, Amy Praestgaard⁴, Gregory St John⁵, Thomas Huizinga⁶, Daniel Aletaha⁷ and Roy Fleischmann⁸, ¹Charité University Hospital Berlin, Berlin, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…
Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Ales Janda⁶, Tilmann Kallinich⁷, Prasad T. Oommen⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Norbert Blank¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, ⁷Charite, Berlin, Germany, ⁸Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
Abstract Number: 1726 • ACR Convergence 2020
Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Patient reported outcomes are integral to measuring patient response to treatment for rheumatoid arthritis (RA). RAPID3 is a patient reported outcome metric that consists…
Abstract Number: 1820 • ACR Convergence 2020
Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity
Margaret Markiewicz¹, Dayvia Russell² and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, Charleston, SC, ².Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the…
Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Naoto Tamura¹, Eiichi Tanaka², Eisuke Inoue³, Yuri Yoshizawa⁴, Shigeru Matsumoto⁵, Hisashi Yamanaka⁶ and Masayoshi Harigai⁷, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Bristol-Myers Squibb K.K., Tokyo, Japan, ⁵Ono Pharmaceutical Co., Ltd., Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, ⁷Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…
Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Uta Kiltz¹, Jan Brandt-Jürgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ³Ambulantes Rheumazentrum, Erfurt, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
Abstract Number: 0834 • ACR Convergence 2020
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Stefano Fiore¹, Lang Chen², Cassie Clinton², Huifeng Yun², Amy Praestgaard³, Kerri Ford³ and Jeffrey R Curtis², ¹Sanofi, Bridgewater, NJ, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Sanofi, Cambridge, MA
Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
Abstract Number: 1083 • ACR Convergence 2020
Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment
Sabina Oreska¹, Hana Storkanova², Maja Spiritovic³, Barbora Hermankova⁴, Michal Vrablik⁵, Karel Pavelka⁶, Ladislav Šenolt⁶, Heřman Mann², Jiří Vencovský⁶ and Michal Tomcik⁷, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁵3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by skeletal muscle and organ involvement and chronic course. Systemic inflammation, limited mobility, and glucocorticoid treatment can have…
Abstract Number: 1273 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients
Rebecca Sadun¹, Jennifer Rogers², Kai Sun¹, Karissa Grier¹, Lisa Criscione-Schreiber³, Mithu Maheswaranathan¹, Jayanth Doss¹ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Many patients with SLE experience symptoms of chronic pain and fatigue, often meeting criteria for fibromyalgia (FM). In this study, we sought to examine…
Abstract Number: 1538 • ACR Convergence 2020
Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Rheumatoid Arthritis Patients in Sustained Clinical Remission
Lene Terslev¹, Cecilie Hegaard Brahe², Merete Hetland³, Stylianos Georgiadis⁴, Karen Ellegaard⁵, Lars Juul⁶, Uffe Døhn⁷, Viktoria Fana¹, Torsten Møller¹, Simon Krabbe¹, Lykke Ørnbjerg¹, Daniel Glinatsi¹, Tuan Khai Huynh⁸, Natalia Manilo⁹, Dorte Vendelbo Jensen¹⁰, Karsten Asmussen⁹, Mikael Boesen¹¹, Zoreh Rastiemadabadi¹², Lone Morsel-Carlsen¹², Jakob Møller¹³, Henrik Røgind¹, Annette Hansen¹⁰, Jesper Nørregaard¹, Søren Jacobsen¹⁴, Niels Steen Krogh¹⁵ and Mikkel Østergaard¹⁶, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ²Center for Rheumatology and Spine diseases, Glostrup, Denmark, ³The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Glostrup, Denmark, ⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Kobenhavn, Denmark, ⁷Center for Rheumatology and Spine Diseasesand COPECARE, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Frederiksberg, Copenhagen, Denmark, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Copenhagen, Denmark, ¹¹department of Radiology, Frederiksberg and Bispebjerg hospitals, Naerum, Denmark, ¹²Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, ¹³Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark, ¹⁴University of Copenhagen, Copenhagen, Denmark, ¹⁵ZiteLab ApS, Frederiksberg, Denmark, ¹⁶Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: There is an increasing interest in tapering or even discontinuing biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients in sustained remission. The…
Abstract Number: 1730 • ACR Convergence 2020
Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
Leonard Calabrese¹, Michael Weinblatt², Nancy Shadick², Cecilie Hegaard Brahe³, Mikkel Østergaard⁴, Merete Hetland⁵, Megan Horton⁶, Darl Flake⁶ and Eric Sasso⁷, ¹Cleveland Clinic, Cleveland, OH, ²Brigham and Women's Hospital, Boston, MA, ³Center for Rheumatology and Spine diseases, Glostrup, Denmark, ⁴Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶Myriad Genetics, Inc., Salt Lake City, UT, ⁷Myriad Autoimmune, South San Francisco, CA
Background/Purpose: To compare the abilities of MBDA score, patient global assessment (PGA) and evaluator global assessment (EGA) to assess risk for radiographic progression (RP), and…
Abstract Number: 1827 • ACR Convergence 2020
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Anca Askanase³, Ed Vital⁴, Joan Merrill⁵, Rubana Kalyani⁶, Gabriel Abreu⁷, Lilia Pineda⁶ and Raj Tummala⁶, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³Columbia University College of Physicians and Surgeons, New York, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].